View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBellicum Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Bellicum Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 04Bellicum Pharmaceuticals Files Form 15Bellicum Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.お知らせ • Feb 22The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).The University of Texas M. D. Anderson Cancer Center agreed to acquire substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) for $8.1 million on November 21, 2023. Pursuant to the asset purchase agreement, MDACC will pay to Bellicum an amount equal to $8.1 million in cash and will assume certain related liabilities. The transaction is subject to receive approval from Bellicum’s stockholders and certain other customary closing conditions. The asset purchase agreement has been approved by the board of directors of Bellicum and The Board of Regents of the University of Texas System (the “UT Board of Regents”), the governing body for the University of Texas System. Matthew Browne, Rowook Park and Matthew Silverman of Cooley LLP acted as legal advisors to Bellicum Pharmaceuticals. Roger J. Griesmeyer of Katten Muchin Rosenman LLP acted as legal advisors to The University of Texas M.D. Anderson Cancer Center.The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) on February 21, 2024. As of January 29, 2024, the transaction has been approved by the shareholders of Bellicum Pharmaceuticals.お知らせ • Jul 08Nasdaq to Delist the Common Stock of Bellicum PharmaceuticalsNasdaq announced on July 6, 2023 that it will delist the common stock of Bellicum Pharmaceuticals, Inc. The company’s securities were suspended on June 2, 2023, and have not traded on Nasdaq since that time.お知らせ • Jun 03Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite IndexBellicum Pharmaceuticals, Inc. has been dropped from NASDAQ Composite Index.お知らせ • May 31Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)As previously disclosed by Bellicum Pharmaceuticals, Inc., pursuant to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2023, on April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol “BLCM".お知らせ • Feb 17Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers SymposiumBellicum Pharmaceuticals, Inc. will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601. These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients. These initial data from 2 cohorts consisted of 8 patients who received lympodepleting chemotherapy (fludarabine + cyclophosphamide) followed by a single dose of 5x106 BPX-601 cells/kg and single (n=3) or weekly (n=5) doses of 0.4 mg/kg rimiducid beginning 7 days following the cell infusion. GoCAR-T cells are designed to function optimally with repeat dosing of rimiducid to induce the co-activation molecules MyD88 and CD40. The trial continues to enroll patients. The next cohorts in the Phase 1 trial will explore higher doses of rimiducid, which in non-clinical studies have been shown to increase GoCAR-T persistence, enhance pro-inflammatory cytokine production, and improve anti-tumor efficacy.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.63, the stock trades at a trailing P/E ratio of 2.3x. Average forward P/E is 39x in the Biotechs industry in Europe. Total loss to shareholders of 94% over the past three years.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 33% share price gain to €1.64, the stock trades at a trailing P/E ratio of 2.4x. Average forward P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 94% over the past three years.Valuation Update With 7 Day Price Move • Dec 13Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.45, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 95% over the past three years.Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €1.51, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 96% over the past three years.Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €1.91, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total loss to shareholders of 95% over the past three years.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 18% share price gain to €2.80, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 23x in the Biotechs industry in Europe. Total loss to shareholders of 95% over the past three years.Reported Earnings • Apr 02Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)Full year 2020 results: Net loss: US$7.72m (loss narrowed 93% from FY 2019).Is New 90 Day High Low • Jan 30New 90-day high: €4.46The company is up 54% from its price of €2.90 on 30 October 2020. The German market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 13% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bellicum Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:BPXA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20232-22-23-23N/A6/30/20232-29-27-27N/A3/31/20232-25-26-26N/A12/31/20222-25-26-26N/A9/30/20222-16-25-25N/A6/30/20226-8-20-20N/A3/31/20226-6-21-21N/A12/31/20216-10-23-23N/A9/30/202167-30-30N/A6/30/202114-43-42N/A3/31/20211-37-49-49N/A12/31/20201-8-57-57N/A9/30/20205-55-57-56N/A6/30/20205-87-62-62N/A3/31/20207-70-70-69N/A12/31/20197-112-78-78N/A9/30/20192-111-86-85N/A6/30/20193-102-84-83N/A3/31/20191-100-82-81N/A12/31/20181-98-76-75N/A9/30/20181-93-70-67N/A6/30/20181-92-74-68N/A3/31/20180-93-80-69N/A12/31/20170-92-85-73N/A9/30/20170-90-87-75N/A6/30/20170-84N/A-69N/A3/31/20170-76N/A-62N/A12/31/20160-69N/A-50N/A9/30/20160-66N/A-48N/A6/30/20160-62N/A-44N/A3/31/20160-56N/A-40N/A12/31/20150-49N/A-36N/A9/30/20150-106N/A-74N/A6/30/20151-97N/A-67N/A3/31/20151-90N/A-61N/A12/31/20142-85N/A-57N/A9/30/20143-14N/A-9N/A6/30/20143-12N/A-10N/A3/31/20142-10N/A-9N/A12/31/20132-9N/A-8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BPXAの予測収益成長が 貯蓄率 ( 0.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BPXAの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BPXAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BPXAの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BPXAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BPXAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/17 15:44終値2023/11/20 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bellicum Pharmaceuticals, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Elemer PirosCantor Fitzgerald & Co.Charles ButlerGuggenheim Securities, LLCBiren AminJefferies LLC5 その他のアナリストを表示
お知らせ • Mar 04Bellicum Pharmaceuticals Files Form 15Bellicum Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.
お知らせ • Feb 22The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).The University of Texas M. D. Anderson Cancer Center agreed to acquire substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) for $8.1 million on November 21, 2023. Pursuant to the asset purchase agreement, MDACC will pay to Bellicum an amount equal to $8.1 million in cash and will assume certain related liabilities. The transaction is subject to receive approval from Bellicum’s stockholders and certain other customary closing conditions. The asset purchase agreement has been approved by the board of directors of Bellicum and The Board of Regents of the University of Texas System (the “UT Board of Regents”), the governing body for the University of Texas System. Matthew Browne, Rowook Park and Matthew Silverman of Cooley LLP acted as legal advisors to Bellicum Pharmaceuticals. Roger J. Griesmeyer of Katten Muchin Rosenman LLP acted as legal advisors to The University of Texas M.D. Anderson Cancer Center.The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) on February 21, 2024. As of January 29, 2024, the transaction has been approved by the shareholders of Bellicum Pharmaceuticals.
お知らせ • Jul 08Nasdaq to Delist the Common Stock of Bellicum PharmaceuticalsNasdaq announced on July 6, 2023 that it will delist the common stock of Bellicum Pharmaceuticals, Inc. The company’s securities were suspended on June 2, 2023, and have not traded on Nasdaq since that time.
お知らせ • Jun 03Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite IndexBellicum Pharmaceuticals, Inc. has been dropped from NASDAQ Composite Index.
お知らせ • May 31Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)As previously disclosed by Bellicum Pharmaceuticals, Inc., pursuant to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2023, on April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol “BLCM".
お知らせ • Feb 17Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers SymposiumBellicum Pharmaceuticals, Inc. will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601. These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients. These initial data from 2 cohorts consisted of 8 patients who received lympodepleting chemotherapy (fludarabine + cyclophosphamide) followed by a single dose of 5x106 BPX-601 cells/kg and single (n=3) or weekly (n=5) doses of 0.4 mg/kg rimiducid beginning 7 days following the cell infusion. GoCAR-T cells are designed to function optimally with repeat dosing of rimiducid to induce the co-activation molecules MyD88 and CD40. The trial continues to enroll patients. The next cohorts in the Phase 1 trial will explore higher doses of rimiducid, which in non-clinical studies have been shown to increase GoCAR-T persistence, enhance pro-inflammatory cytokine production, and improve anti-tumor efficacy.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.63, the stock trades at a trailing P/E ratio of 2.3x. Average forward P/E is 39x in the Biotechs industry in Europe. Total loss to shareholders of 94% over the past three years.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 33% share price gain to €1.64, the stock trades at a trailing P/E ratio of 2.4x. Average forward P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 94% over the past three years.
Valuation Update With 7 Day Price Move • Dec 13Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.45, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 95% over the past three years.
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €1.51, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 96% over the past three years.
Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €1.91, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total loss to shareholders of 95% over the past three years.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 18% share price gain to €2.80, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 23x in the Biotechs industry in Europe. Total loss to shareholders of 95% over the past three years.
Reported Earnings • Apr 02Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)Full year 2020 results: Net loss: US$7.72m (loss narrowed 93% from FY 2019).
Is New 90 Day High Low • Jan 30New 90-day high: €4.46The company is up 54% from its price of €2.90 on 30 October 2020. The German market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 13% over the same period.